Newsletter - AHCIPA

ACO REACH Challenging to Succeed in First Year But Tools Can Help

To succeed in ACO Reach, groups need to accurately identify the social determinants of health (SDoH) barriers affecting their patient population and determine which barriers could be addressed effectively. Some technology can accurately note specific SDoH risk factors facing a given patient and offer targeted intervention recommendations based on that patient’s unique SDoH risk factors.

Mike Ward

Mental Health Startup Combining Psychiatry with Novel Treatments Launches with $5.4M in Funding

Being Health, a startup that launched last week, offers a care team that includes psychiatrists, psychotherapists, nurse anesthetists, functional medicine physicians, nutritionists, acupuncturists and care advocates. It serves patients both virtually and in person.

Marissa Plescia

Transforming Diagnosis and Treatment of Pediatric Pneumonia Through Point-Of-Care Lung Ultrasound

Point-of-care lung ultrasound – also known as lung POCUS – is a safer, more reliable alternative to X-ray in diagnosing pneumonia that provides information quickly. Yet it’s not widely considered the standard of care.

Dr. Stephen Erickson

We’ve Actually Treated Tens of Thousands of People on Ozempic to Date – Here’s What Really Happens and What It Likely Means for Solving Our Obesity Epidemic

We and our collective organizations’ providers have treated 10,000’s of Americans, who suffer from obesity and/or Type 2 diabetes with GLP-1 drugs. And we believe we have important observations to share.

Dr. Jeff Stanley

Healthcare Moves: A Monthly Summary of Hires and Layoffs

Here is a selection of recent executive hires, promotions and layoffs occurring across the healthcare industry.

Katie Adams

Biogen Says Goodbye to Beleaguered Alzheimer’s Drug Aduhelm

Biogen has returned its Aduhelm rights to Neurimmune, the company that initially developed the antibody Alzheimer’s disease drug. But Biogen isn’t abandoning Alzheimer’s, and its pipeline includes drugs that take other approaches to the neurodegenerative disorder.

Frank Vinluan